FILE:BMY/BMY-8K-20040526062435.txt.gz
EVENTS:	Other events
TEXT:
ITEM: Other events
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
BRISTOL-MYERS SQUIBB COMPANY
 
 
 
 
Item 5.                    OTHER EVENTS
 
               
As disclosed in Bristol-Myers Squibb Company's (Company) Quarterly Report on Form 10-Q for the first quarter of 2004, filed on May 10, 2004:  (1) on April 27, 2004 the Company announced an agreement to settle patent litigation with Pharmachemie B.V. (a subsidiary of Teva Pharmaceutical Industries), in relation to which the Company will, in addition to continuing to distribute PARAPLATIN (carboplatin), sell product to Pharmachemie allowing it to distribute an unbranded version of carboplatin commencing June 24, 2004, subject to several conditions including approval by the Federal Trade Commission; and (2) based on studies evaluating the use of carboplatin in the pediatric population, the Company on April 30, 2004 obtained from the Food and Drug Administration a six-month extension of marketing exclusivity for PARAPLATIN beyond the expiration of its primary patent, which expired on April 14, 2004.
On May 25, 2004, the FTC announced it issued advice to the Company that the agreement does not raise issues under Section 5 of the Federal Trade Commission Act.  The Company expects Pharmachemie B.V. will sell carboplatin beginning on June 24, 2004.
 
 
 
 
 
                Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Dated: May 25, 2004


